Risk factors

RP1’s resubmitted BLA faces unresolved FDA concerns and potential advisory committee scrutiny in late July 2026.

Solana-specific technical, staking, governance and network-control risks dominate the disclosure.

XRP's value is exposed to extreme volatility, concentration among large wallets, and the Fund's lack of diversification.

Liquidity deteriorated sharply: cash fell to $3.4 million, working capital became negative $12.2 million, and operations used $26.5 million.

Sales concentration among three domestic channel partners fell from 41% to 34% of fiscal-year sales.

AI is now a dedicated risk, covering data quality, cyberattacks, evolving laws, privacy, intellectual property and governance.

Third-party representatives now generate 82% of net revenue, with two organizations alone contributing 43% and 25%.

New risks emphasize commercialization execution, cybersecurity and software-enabled hospital systems, and supplier concentration for LungFit PH.

2025 tariffs under IEEPA could raise sourcing costs and constrain pricing and long-term planning.

FCC shutdown risk is newly explicit because licensing delays could prevent Anterix from meeting customer obligations and commercializing 900 MHz spectrum.

AI infrastructure and data-center expansion now drive major demand, execution and technology risks.

Operations now depend on one contract manufacturer handling production, spare-parts warehousing, and logistics.